Aptorum Group shares climb after drug study data

Aptorum

24/05/2021 14:25

** Shares in clinical stage biopharma company Aptorum Group
 APM.O  up ~6.7% at $2.54 in premarket trading on Monday after
it released interim Phase I clinical trial progress for ALS-4
targeting staphylococcus aureus, including MRSA 
    ** It also announced that it is on track to start clinical
studies in Q3, with guidance from the U.S. FDA, for sact-1
targeting neuroblastoma  urn:newsml:reuters.com:*:nBw48KtSla
    ** Aptorum said phase 1 ALS-4 study would continue after two
initial cohorts of the single dose ascending dose (SAD) part of
the trial in healthy male and female adult subjects was
completed with no serious adverse events observed
    ** APM closed at $2.38 on Nasdaq on Friday. Its high so far
for 2021 was $4.94 (Jan). The stock had spiked as high as $14.23
on Sept 29 and has traded below $5 since then   

 ((sinead.carew@thomsonreuters.com; +1 (646) 223 6186; Reuters
Messaging: sinead.carew.thomsonreuters.com@reuters.net))